The global demand for Atherosclerosis Market is presumed to reach the market size of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% under the study period 2022 - 2028.
Atherosclerosis, also called as atherosclerotic cardiovascular disease is a disorder in which cholesterol plaque builds up in the walls of the circulatory system's arteries and blood vessels, reducing blood flow and eventually leading to heart disease. The thickening, hardness, and loss of flexibility of the artery walls are known as atherosclerosis. The damage to the endothelium caused by smoking, high cholesterol, and high blood pressure begins atherosclerosis—plaque forms due to this damage. Calcium, cholesterol, fat, and other elements found in the blood make up plaque. This can result in significant complications such as a stroke, a heart attack, or even death. Atherosclerosis can harm any artery in the body, including those in the legs, brain, heart, arms, pelvis, and legs, resulting in various symptoms depending on which ones are affected. The three main types of cardiovascular problems produced by atherosclerotic plaques are coronary artery disease, cerebrovascular disease, and peripheral artery disease.
Market Dynamics
The high prevalence of atherosclerosis and increased drug approvals and government initiatives are driving the global atherosclerosis market. Furthermore, advancements in the pharmaceutical and biotechnological sectors or industries and an increase in demand for novel treatments are some of the factors driving the market growth. The examined atherosclerosis market is expected to be boosted by a sedentary lifestyle, which leads to a high prevalence of cardiovascular illnesses and raising awareness of treatment options due to an increase in the senior population and an increase in the incidence rate of heart attacks caused by coronary heart disease or atherosclerosis. A crucial element driving the global atherosclerosis market is innovative treatment options (both branded and generic). However, the worldwide atherosclerosis market is likely to be restrained over the forecast period due to a reliance on symptom-based treatment in certain situations and the limited efficacy and side effects of currently available medications.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of atherosclerosis. The growth and trends of atherosclerosis industry provide a holistic approach to this study.
Market Segmentation
This section of the atherosclerosis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Therapy
- Medications
- Cholesterol-Lowering Medications
- Antiplatelet Drugs And Anticoagulants
- Beta Blockers
- Diuretics, Or Water Pills
- Angiotensin Converting Enzyme (Ace) Inhibitors
- Others
By Surgery
- Bypass Surgery (Coronary Artery Bypass Grafting (Cabg))
- Angioplasty
- Atherectomy
By Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Retail Pharmacies
- Clinics
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Atherosclerosis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Atherosclerosis Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the atherosclerosis market include GlaxoSmithKline plc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc., Anthera Pharmaceuticals, Novartis AG, Sanofi, Johnson and Johnson, Bayer AG, The Medicine Company, Cardium Therapeutics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.